News
NETRF Clinical Trial Roundup: January 2026
Highlights from recent clinical trial developments in neuroendocrine cancer Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly
New Blood Test May Help Guide Neuroendocrine Cancer Therapy
By Anna C. Greene, PhD, NETRF Chief Scientific Officer One of the most exciting developments in neuroendocrine cancer treatment in recent years has been the
What New Data Tells Us About the Neuroendocrine Cancer Diagnostic Journey
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we often hear a familiar story: symptoms that don’t
The NETRF Year in Research: 2025
Thank you for your generous support. Because of you, 2025 was a year of meaningful momentum in neuroendocrine cancer research. Through 50 active NETRF-funded projects
GLP-1 Drugs and Neuroendocrine Cancer: What a New Study Suggests
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
Looking Ahead: Hope, Discovery, and Momentum from the 2025 NETRF Research Symposium
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
The Grewal Research Update on NANETS 2025
By Udhayvir Singh Grewal, MD, Assistant Professor of Medical Oncology, Emory University School of Medicine Guest Contributor The Annual NANETS Multi-Disciplinary Symposium 2025 was a
SPORE Grant Awarded to the University of Iowa to Study Neuroendocrine Cancer
Congratulations to Dr. Dawn Quelle, NETRF Board of Scientific Advisors co-chair, and the team at the University of Iowa Health, for winning a $10.7 million
Clinical Advances, Research Progress, and Patient Advocacy Celebrated at NANETS Annual Meeting
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates
Understanding Patient Perspectives on Radioligand Therapy for GEP-NETs
A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand